Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06369246RecruitingPhase 2
Five-session radiation for advanced prostate cancer
This trial is testing a shorter course of radiation therapy (5 sessions instead of many) for men with prostate cancer that is at a higher risk but hasn't spread. The goal is to see if fewer, higher-dose treatments work as well while being more convenient.
Houston, TexasAges 18 years+ - NCT06378346RecruitingPhase 2
Glycyrrhizin for prostate cancer before surgery
This trial tests a natural substance called glycyrrhizin (found in licorice root) before prostate surgery. It aims to see if it can help control prostate cancer. You would take it for a short time before your planned prostate removal.
Chicago, IllinoisAges 18 years+ - NCT06320067RecruitingPhase 3
Testing treatments for metastatic hormone-sensitive prostate cancer
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
BarnsleyAges 18 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT06305390RecruitingPhase 2
PSMA PET/MRI for prostate cancer diagnosis
This trial tests a new, all-in-one PET/MRI scan to see if it can better find aggressive prostate cancer in men who need a biopsy. It may help avoid unnecessary biopsies and give a clearer picture of your condition.
Milan, MilanoAges 18 years+ - NCT02705846Recruiting
Study tracks outcomes in men with inherited prostate cancer risks
This study looks at how prostate cancer diagnoses and treatments turn out over time. It compares men who carry rare inherited gene changes that raise prostate cancer risk with men who do not, to better understand which treatments and outcomes may differ.
Sutton, SurreyAges 18 years+ - NCT06190899RecruitingPhase 1/Phase 2
Testing gedatolisib plus darolutamide in advanced prostate cancer
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT06202248Recruiting
DaRT radiation therapy for prostate cancer that has returned
This trial tests a new type of radiation using tiny alpha-emitting seeds placed directly into the tumor. It is for people whose prostate cancer came back in the gland after initial treatment but hasn't spread elsewhere.
HaifaAges 18–120 - NCT06200259Recruiting
Reducing Bowel Side Effects in Prostate Cancer Proton Therapy
This study tests a way to reduce stomach and bowel side effects of proton therapy for prostate cancer. It uses special software to place the proton beam more carefully, which may protect nearby organs.
Knoxville, TennesseeAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+ - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New Haven, ConnecticutAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT05754580Recruiting
Boost radiation for intermediate or higher-risk prostate cancer
This study tests a stronger, focused radiation plan for intermediate to higher-risk prostate cancer. It combines a high-dose internal radiation “boost” with external radiation to try to improve cancer control while keeping side effects manageable.
Omaha, NebraskaAges 19 years+ - NCT06067269RecruitingPhase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Los Angeles, CaliforniaAges 18 years+ - NCT06072911Recruiting
Men's health after prostate cancer surgery study
This study looks at how men recover control of urine and sexual function after prostate removal surgery. It also tests if a 12-week exercise program can help improve these functions.
Edmonton, AlbertaAges 18 years+ - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Birmingham, AlabamaAges 18 years+ - NCT05948657Recruiting
PSMA PET-CT scan for men on prostate cancer surveillance
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05931419Recruiting
Radiation versus surgery for high-risk prostate cancer
This trial compares two standard treatment options—radiation or surgery—for people with high-risk prostate cancer that has not spread. The goal is to see which approach works better for long-term cancer control and side effects.
AlkmaarAges 50–75 - NCT05873192RecruitingPhase 2
Talazoparib plus enzalutamide before prostate surgery
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Houston, TexasAges 18 years+ - NCT05847166Recruiting
Testing a PSMA-targeted treatment for prostate cancer
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
Bydgoszcz, PolandAges 18 years+ - NCT05838716RecruitingPhase 3
Vitamin D During Hormone Therapy for Prostate Cancer
This trial studies whether taking vitamin D while you are on prostate hormone therapy (ADT) affects your health outcomes. It may help by keeping vitamin D levels in a safe range during treatment.
Newark, DelawareAges 50 years+ - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 431 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.